TBE/iStock Editorial via Getty Images
The US Court of Appeals has reportedly ruled that a whistleblower case be filed against Novartis (New York Stock Exchange:same) due to alleged kickbacks involving the multiple sclerosis drug Gilenya, can move forward.
The 2nd U.S. Circuit Court of Appeals in Manhattan ruled that whistleblower Stephen Camburn could
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458292255/image_458292255.jpg?io=getty-c-w750
Source link